Hormonal
GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 agonists (e.g., tirzepatide) provide superior glycemic control and significant body weight reduction compared to standard therapies, establishing them as cornerstone treatments for type 2 diabetes and obesity.
If you have Type 2 Diabetes or Obesity, GLP-1 and dual-agonist medications are now considered cornerstone treatments that offer better blood sugar control and weight loss than older therapies, especially if you have heart or kidney risks. These drugs work by mimicking gut hormones to increase insulin, slow digestion, and reduce appetite. While they can cause stomach issues, starting with a low dose and slowly increasing it helps your body adjust. Oral versions are available for some drugs, removing the need for injections for those who prefer it.
These pharmaceutical drugs provide significant glycemic control by stimulating insulin secretion, suppressing glucagon secretion. It also reduces body weight... GLP-1 agonists and combination drugs demonstrate not only glucose-lowering and anorexigenic properties but also nephro- and cardioprotective effects... Phase III clinical trials (SURPASS and SURMOUNT) showed that tirzepatide outperforms semaglutide in both HbA1c reduction and weight loss
Why this rating
The claims are supported by references to large international clinical trials (SUSTAIN-6, PIONEER, SURPASS, SURMOUNT) and FDA approvals.
Source
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Arthur Anatolievich Lee et al. · Medical Sciences · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →